Navigation Links
Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
Date:5/28/2009

atic colorectal cancer," said Robert De Jager, M.D., chief medical officer of Poniard. "We are continuing to observe the study participants to obtain overall survival data, and expect those data later this year. The new PFS, tumor response and neurotoxicity data provide the rationale to consider additional trials to develop picoplatin as a preferred platinum for the treatment of metastatic colorectal cancer."

Analyst and Investor Briefing

Poniard will host an investor event in Orlando on Sunday, May 31, 2009. Presentations will begin promptly at 6:00 p.m. Eastern Time. The event will feature presentations and discussion with expert oncologists, including Richard Goldberg, M.D., of the University of North Carolina's Lineberger Comprehensive Cancer Center, William Oh, M.D., of Harvard Medical School, and David S. Ettinger, M.D., of the Kimmel Comprehensive Cancer Center at Johns Hopkins, in addition to members of Poniard's senior management team. The analyst meeting will also be simultaneously Webcast from Poniard's Web site at www.poniard.com and will remain available for 30 days following the live event.

About Colorectal Cancer

CRC is the third most common cancer in both American men and women, and the third leading cause of cancer death in the U.S. In 2008, an estimated 148,810 new cases of colon and rectal cancer were expected to be diagnosed in the U.S., with an estimated 49,960 deaths.(1) A FOLFOX-containing regimen is the current standard of care but is associated with a high incidence of neuropathy. Discontinuation of oxaliplatin from FOLFOX is recommended by the National Comprehensive Cancer Network (NCCN) Practice Guidelines in Oncology (v.2.2009) after three months of therapy or sooner if significant neurotoxicity (> Grade 3) occurs, with other drugs maintained until the time of tumor progression.

About Picoplatin

Picoplatin
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
2. Poniard Pharmaceuticals to Present New Data from Phase 2 Clinical Trials of Picoplatin in Multiple Tumor Types at the 45th Annual Meeting of the American Society of Clinical Oncology
3. Poniard Completes Patient Enrollment Target in Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
4. Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update
5. Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin
6. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
7. Poniard Announces Positive Efficacy and Safety Data From Phase 1 Trial of Picoplatin in Multiple Tumor Types Including Ovarian Cancer
8. Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer
9. Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer
10. Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting
11. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Research and Markets has announced ... Market 2014-2018" report to their offering. ... that results in demyelination, axonal transection, and neurodegeneration. The ... by the immune system, which targets neurons within the ... disease in which the damage of the myelin sheath ...
(Date:8/29/2014)... , Aug. 29, 2014  Pacific Medical Data Solutions ... new website design . The main website, along with ... the company,s new services and content relevant to the ... new streamlined design, viewers can now better understand how ... care practices and create a more visible platform about ...
(Date:8/29/2014)... Aug. 29, 2014 Research and Markets ... Soft Tissue Repair Devices Market 2014-2018" report to ... the mass of cells that connect, support, or surround ... such as tendons, ligaments, cartilage, fascia, and other fibrous ... these tissues with age result in wear and tear ...
Breaking Medicine Technology:Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3PMDS Announces New Website 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 3
... Feb. 24 Biopharmaceutical manufacturers, responsible ... recombinant proteins, monoclonal antibodies, and vaccines -- are ... the type of product being assessed. A ... routine sampling and testing requirements associated with the ...
... Kensey Nash Corporation (Nasdaq: KNSY ) announced ... (IDE) application to the U.S. Food and Drug Administration ... biomaterials technology for treating articular cartilage defects of the ... Repair Device, which consists of a proprietary bi-phasic, bioresorbable ...
Cached Medicine Technology:White Paper Explains Aspects of Testing From Purified Bulk Drug Substance to Sterile Liquid Final Drug Product 2Kensey Nash Announces IDE Submission for Cartilage Repair Device 2Kensey Nash Announces IDE Submission for Cartilage Repair Device 3Kensey Nash Announces IDE Submission for Cartilage Repair Device 4
(Date:8/29/2014)... across the Arabian Peninsula and spread to Europe several ... of several hundred people since its discovery in 2012. ... how easily the pathogen spreads from human to human. ... the University of Bonn have now come to the ... transmission is low. Still, a third of infected persons ...
(Date:8/29/2014)... Glendale Botox experts at Glenoaks Laser Center are ... of September. This special offer features 10 free units of ... can take advantage of this special offer to completely transform ... work with patients to determine if Botox or Juvederm is ... , Botox is a treatment made from the botulinum toxin. ...
(Date:8/29/2014)... VHA Central Atlantic recognized Novant Health ... honoring nine facilities for meeting or exceeding national performance ... Health, providing quality, affordable healthcare for our communities has ... executive vice president and chief medical officer. “These awards ... for each and every one of our patients.” , ...
(Date:8/29/2014)... TX (PRWEB) August 29, 2014 PreDiabetes ... off the fall season by offering Web shoppers a 20% ... PreD Store , the Company’s online healthy living shop, beginning ... should be top priority when heading into the chilly fall ... lifestyle habits. During this season, people usually ditch the healthy ...
(Date:8/29/2014)... August 29, 2014 Many Americans are ... keep diabetes type 2 at bay, patients should consider ... make the necessary lifestyle changes. While some diabetes risk ... history, advanced age, or belonging to certain ethnic groups, ... – their weight. Carrying extra pounds, especially in the ...
Breaking Medicine News(10 mins):Health News:MERS: Low transmissibility, dangerous illness 2Health News:MERS: Low transmissibility, dangerous illness 3Health News:Glenoaks Laser Center is Now Offering a Special Promotion on Botox for the Month of September 2Health News:Novant Health Recognized for Excellence in Clinical Care 2Health News:Novant Health Recognized for Excellence in Clinical Care 3Health News:PreDiabetes Centers Online Store Launches Fall Savings Event 2Health News:Diet Doc Announces Specialized Diet Plans that Help Patients Prevent Diabetes by Stabilizing Blood Sugar Levels and Losing Excess Fat 2Health News:Diet Doc Announces Specialized Diet Plans that Help Patients Prevent Diabetes by Stabilizing Blood Sugar Levels and Losing Excess Fat 3
... has led to the development of proposals to dump about 800 ... end of the month. ,The move follows the ... six months should stay on a list. ,Patients ... within six months are referred back to their GP for monitoring. ...
... have identified key compounds that stimulate stem cell growth ... is set to appear in the September 2006 issue ... one day lead to restored function for people who ... sclerosis, and a wide range of neurological disorders. The ...
... doctors in North Karnataka, cautioned by the health and ... and not to harass them. // ,The ... take action against doctors harassing and denying treatment to ... of the first anniversary celebration of ‘Ashodaya’, which is ...
... to launch a new vaccination project to protect ... vaccination against pneumococcal meningitis will also be integrated ... meningitis is very serious," Diane McConnell, manager of ... die or be left with very severe after ...
... nitrogen-containing compounds that food producers use to cure meats may ... says a new study. // ,Previous studies have found ... study by Graham Barr at Columbia University Medical Center in ... the affect on lung function in humans, reported the online ...
... Mukesh Haikerwal, today urged all Australians to think about ... desire to donate organs.// ,Research published in the ... for transplant are harvested from only a fraction of ... found that, in many instances, organs are not donated ...
Cached Medicine News:Health News:800 Patients to be Dumped from Hospital Waiting Lists 2Health News:Action Against Doctors Harassing HIV/AIDS Patients 2Health News:AMA Urges Organ Donors to Speak Up 2
... Dehydroepiandrosterone sulfate (DHEA-S) is the sulfate ... and by enzymatic conversion of DHEA in ... major C19 steroid secreted by the adrenal ... and estrogen biosynthesis. DHEA possesses relatively weak ...
... Dehydroepiandrosterone sulfate (DHEA-S) is the sulfate ... and by enzymatic conversion of DHEA in ... major C19 steroid secreted by the adrenal ... and estrogen biosynthesis. DHEA possesses relatively weak ...
... sulfate ester of DHEA, derived from sulfated ... in adrenal and extradrenal tissues. DHEA is ... adrenal cortex, and is a precursor for ... weak androgenic activity, which for unsulfated DHEA ...
... kit is based on the competition principle ... of DHEA-S present in the sample and ... horse-radish peroxidase compete for the binding sites ... the wells. After one hour incubation the ...
Medicine Products: